Board of Directors

Rahul D. Ballal, PhD, PhD

Chief Executive Officer

Dr. Ballal is CEO of Imara and has more than 15 years of life sciences experience in business development, strategic partnerships, venture capital, and company financing. He joined from Northern Biologics and Versant Ventures where he was Chief Business Officer and an Entrepreneur-in-Residence, respectively. At Northern, he built a first-in-class immuno-oncology portfolio, led a broad strategic partnership with Celgene, and managed several key functional roles at the executive level. At Versant, he negotiated foundational assets for existing portfolio and new companies, sourced several new deals, and participated in investment team activities. Previously, Dr. Ballal was Vice President, Business Development at Flexion Therapeutics, where he led several business development transactions, supported multiple functions during the initial public offering, and completed a key $175MM strategic partnership with Patheon UK, for dedicated commercial manufacturing. Prior to Flexion, he held business development and leadership positions at Novartis Venture Fund; Broad Institute of MIT and Harvard; and Redmind Inc. Dr. Ballal earned a Bachelor’s degree in Biology from Brown University, a Master’s degree in Bioinformatics from Johns Hopkins University and a Ph.D. in Biochemistry from Georgetown University. He is also a Kauffman Fellow.

Read More

David M. Mott, Chairman

General Partner, New Enterprise Associates

Dave Mott joined New Enterprise Associates in September 2008 as a General Partner primarily focused on biopharmaceutical investments. Dave leads NEA’s healthcare investing practice which typically comprises 30% to 40% of each fund, or roughly $750 million to $1 billion of healthcare venture investments every three to four years. The firm invests across all stages and geographies and is a leading investor across all healthcare sectors.

Prior to joining NEA, Dave was President and Chief Executive Officer of MedImmune, subsidiary of AstraZeneca Plc, and Executive Vice President of AstraZeneca. Dave joined MedImmune in 1992 and served in roles of increasing responsibility including Chief Operating Officer, Chief Financial Officer, President and from 2000 – 2008 Chief Executive Officer as the company grew from a venture-backed startup (founded in 1988) into one of the top five biotechnology companies in the world. Ultimately, he led the sale of MedImmune to AstraZeneca in June 2007 for $15.6 billion. In 2002, Dave founded MedImmune Ventures and chaired its investment committee through his departure from MedImmune. At the time of his departure in July 2008, MedImmune had annual revenues in excess of $1.5 billion, annual R&D in excess of $650 million and approximately 3,000 employees. Prior to joining MedImmune, Dave was a Vice President in Health Care Investment Banking at Smith Barney, Harris Upham & Co., Inc. where he focused on public and private equity and debt financings as well as mergers and acquisitions. He received a bachelor of arts degree in economics and government from Dartmouth College.

Dave is currently Chairman of 3-V Biosciences, Ardelyx, Cydan, Mersana, Prosensa, TESARO, and Zyngenia and is a director of Adaptimmune, Edimer Pharmaceuticals, and Epizyme.  He has previously been a director of MedImmune, Shire Pharmaceuticals, Ambit Pharmaceuticals, Omthera Pharmaceuticals, Rib-X Pharmaceuticals and Conceptis.

Read More

Kim Andersen, PhD

Senior Vice President and Head of Research, H. Lundbeck A/S

Kim Andersen, PhD, is Senior Vice President and Head of Research at Lundbeck. He is member of Lundbeck’s R&D Executive Committee.

He started his career with Lundbeck in 1989 and has held different positions within medicinal chemistry including five years as head of department in Denmark and Vice President of Medicinal Chemistry at Lundbeck Research USA, Inc.(formerly Synaptic Pharmaceuticals). In 2006 he returned to the headquarters in Denmark and took on the position as Director of Research Operations and Project Portfolio Management Research, a position he held until becoming Vice President of the Danish research site in 2008.

Kim Andersen holds a MSc in Chemical Engineering and a PhD from the Danish School of Pharmacy, Copenhagen.

Read More

Mette Kirstine Agger, MBA

Managing Partner, Lundbeckfond Ventures

Mette Kirstine was previously co-founder and CEO of 7TM Pharma A/S and has a broad international experience within biotech/life science covering business development and licensing, management and financing. Prior to founding 7TM Pharma, Mette was part of the management team of NeuroSearch A/S responsible for business development and licensing. She started her career as Patent Agent and has over the years co-founded several biotech companies. Mette has been appointed to numerous board positions both in private and public companies. Mette Kirstine Agger graduated as Biologist from the University of Copenhagen and has an MBA.

Mette is a board member of Cydan Development, Psioxus, scPharmaceuticals, Thesan Pharmaceuticals, Veloxis and Vtesse.

Read More

Barbara J. Dalton, PhD

Vice President of Venture Capital, Pfizer Venture Investments

Barbara Dalton joined Pfizer in 2007 to manage the Pfizer Ventures Investments team within Worldwide Business Development. She is responsible for growing their corporate venture activities, managing the corporation’s private equity portfolio, advising on structured equity transactions and driving novel transactions to achieve corporate objectives. Dr. Dalton has more than 20 years of corporate venture capital experience in the pharmaceutical industry supporting and managing teams involved in indirect and direct health care investments in more than 40 funds and over 100 companies in the U.S. and Europe.  She has had direct investing responsibility for biotechnology therapeutic and platform companies, as well as some healthcare IT and service businesses.  She is currently on the board of Cydan, Vtesse, Ixchelsis, The Accelerator Crop, Petra and Lodo and supports several other PVI portfolio companies as a board observer.  Dr. Dalton began her pharmaceutical career as a research scientist in immunology at SmithKline and French Laboratories and joined their venture capital group, SR One, Limited in the early 1990’s. She was also a founding member and General Partner with EuclidSR Partners, a private venture capital firm, where SmithKline (now GSK) was a leading limited partner.

Dr. Dalton has also been supportive of the many regional and national organizations encouraging innovative startups in health care. She chaired the Philadelphia regional venture investors association, (fka the MAC Alliance), and has been a member of the National Venture Capital Association Board. She also supported the venture philanthropy efforts of the Institute for the Study of Ageing as a Board member. Currently she is the chair of the advisory board for the health care sector of the New York City Investment Fund and an advisor to the Dean of the Eberly College of Science, at Penn State where she received her undergraduate degree.  She received a PhD in microbiology and immunology from The Medical College of Pennsylvania (now the Drexel University College of Medical School).

Read More

Carl Goldfischer, MD

Managing Director, Bay City Capital

Carl Goldfischer, MD, is a Managing Director of Bay City Capital, and has been with the firm since 2000.  He has invested across all subsectors within the life sciences industry and his expertise spans both private and public markets.  In addition, he brings deep operational experience in finance, clinical trial development, and clinical medicine.

During his career, Dr. Goldfischer has lead and served on the board of directors of innumerable public and private companies including: Epizyme, MAP Pharmaceuticals, Oculex, Cymabay, Cydan and Pharmakea. Most recently his was the founder and is Executive Chairman of Bridge Medicines, a novel partnership between Bay City Capital, Memorial Sloan Kettering, Rockefeller University, Weill Cornell Medicine and Takeda Pharmaceutical Company. This novel partnership aims to take programs from the universities laboratories, seamlessly through human proof of concept.  

Prior to joining Bay City Capital, Dr. Goldfischer was Chief Financial Officer of publicly traded biotech company ImClone Systems where he oversaw financial operations and strategic planning.  Previously, he was a Health Care Research Analyst with the Reliance Insurance Company and was a Director of Research at D. Blech & Co.  He began his career as a radiation oncologist at Montefiore Hospital, part of the Albert Einstein College of Medicine.  Dr. Goldfischer received an MD with honors in Scientific Research from Albert Einstein College of Medicine and a BA from Sarah Lawrence College.

Read More

Joel S. Marcus, Board Observer

Chairman, Chief Executive Officer & Founder, Alexandria Real Estate Equities, Inc.

Joel S. Marcus has served as Chairman of Alexandria Real Estate Equities’ Board of Directors since May 2007, Chief Executive Officer since March 1997, President since February 2009 and a Director since the Company’s inception in 1994. Mr. Marcus co-founded Alexandria Real Estate Equities, Inc. in 1994, Alexandria Venture Investments in 1996, and the annual Alexandria Summit in 2011.

Previously, Mr. Marcus was a partner at the law firm of Brobeck, Phleger & Harrison LLP, specializing in corporate finance and capital markets, venture capital and mergers and acquisitions. He also served as General Counsel and Secretary of Kirin-Amgen, Inc., a joint venture that financed the development of, and owned patents to, two multibillion dollar genetically engineered biopharmaceutical products. Mr. Marcus was formerly a practicing certified public accountant and tax manager with Arthur Young & Co. specializing in the financing and taxation of REITs.

Mr. Marcus serves on the Boards of the Accelerator Corporation, of which he was one of the original architects and co-founders, Foundation for the National Institutes of Health (FNIH), Intra-Cellular Therapies, Inc., Multiple Myeloma Research Foundation (MMRF) and the Partnership for New York City. Mr. Marcus received the Ernst & Young 1999 Entrepreneur of the Year Award (Los Angeles – Real Estate).

Mr. Marcus received his undergraduate and JD degrees from the University of California, Los Angeles.

Read More

James McArthur, PhD

Founder of Imara and President, R&D of Cydan II, Inc.

Dr. James McArthur brings 25 years experience in drug development. He is a founder of 4 companies, has 25 publications in leading journals and over 15 patents in rare diseases, gene therapy, oncology and immunology.

James is a founder, a member of the Board of Directors and was CEO of Imara, the second spinout of Cydan, developing IMR-687 for the treatment or rare hemoglobinopathies. He was also a founder of Cydan’s spinout developing therapies for Niemann Pick type C, Vtesse, which was acquired by Sucampo, and serves as a member of the Board of Directors of Nightstar Therapeutics, a public company focused on developing gene therapies for rare retinal diseases. He also serves as a member of the Board of Directors and Scientific Advisory Board of the Friedreich’s Ataxia Research Alliance (FARA) a leading patient advocacy group ( 

Before co-founding Imara in 2016, Vtesse in 2015 and Cydan in 2013, James was an entrepreneur-in-residence at HealthCare Ventures. There he helped create and then served as Chief Scientific Officer of Synovex Co., where he invented and led the development of SDP051 a treatment for rheumatoid arthritis. Synovex, renamed Adheron, was acquired by Roche and SDP051 is in a Phase 2c study in treatment refractory RA patients.

Previously, he was vice president of preclinical development for Phylogix Inc, a stem cell biology company, and acting head of research and Principal Scientist at Cell Genesys Inc, a leader in gene therapy. He also was a Senior Scientist at Somatix Therapy, which was acquired by Cell Genesys.

He obtained a PhD in biochemistry and oncology at McGill University of Montreal, and was a post doctoral fellow studying Immunology at Massachusetts Institute of Technology in Cambridge and the University of California at Berkeley.

Read More

Sara Nayeem, MD

Partner, New Enterprise Associates

Sara joined NEA’s healthcare team in 2009 and focuses on investments in biopharmaceutical companies. She serves on the boards of Mersana, Cydan, Vtesse and Therachon, and as a board observer for Loxo Oncology (LOXO), Ziarco, Clementia, Millendo, and NightstaRx. She previously served as a board observer for Tesaro (TSRO), Epizyme (EPZM), Omthera (acquired by AstraZeneca), and Zyngenia. She has also been involved in NEA’s investments in Prosensa (acquired by BioMarin), 3-V Biosciences, Edimer, XTuit, and Proteostasis.

Prior to joining NEA, Sara was an Associate with Merrill Lynch’s Global Healthcare Group, where she advised biotechnology, pharmaceutical and medical device companies on numerous mergers, acquisitions and financing transactions. Previously, she worked as an Investment Banking Analyst at Morgan Stanley. She has conducted basic science research in mammalian cardiac development and clinical research in age-related macular degeneration.

Sara concurrently earned her MD (cum laude) and MBA from Yale University, where she was a Yale MBA Scholar. She received her AB (magna cum laude) in Biology from Harvard University.

Read More